Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The effect of nintedanib on health-related quality of life in Japanese patients with progressive fibrosing interstitial lung diseases: A subset analysis of the INBUILD trial.
Inoue Y, Kitamura H, Okamoto M, Ogura T, Nishioka Y, Kuwana M, Taniguchi A, Ito T, Rohr KB, Suda T. Inoue Y, et al. Among authors: rohr kb. Respir Investig. 2024 Apr 30;62(4):589-596. doi: 10.1016/j.resinv.2024.04.008. Online ahead of print. Respir Investig. 2024. PMID: 38692040 Free article.
Effects of nintedanib on disease progression and safety in Japanese patients with progressive fibrosing interstitial lung diseases: Further subset analysis from the whole INBUILD trial.
Ogura T, Suda T, Inase N, Nishioka Y, Azuma A, Okamoto M, Takizawa A, Ito T, Rohr KB, Inoue Y. Ogura T, et al. Among authors: rohr kb. Respir Investig. 2022 Nov;60(6):787-797. doi: 10.1016/j.resinv.2022.06.009. Epub 2022 Aug 1. Respir Investig. 2022. PMID: 35927208 Free article. Clinical Trial.
Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study.
Maher TM, Stowasser S, Nishioka Y, White ES, Cottin V, Noth I, Selman M, Rohr KB, Michael A, Ittrich C, Diefenbach C, Jenkins RG; INMARK trial investigators. Maher TM, et al. Among authors: rohr kb. Lancet Respir Med. 2019 Sep;7(9):771-779. doi: 10.1016/S2213-2600(19)30255-3. Epub 2019 Jul 17. Lancet Respir Med. 2019. PMID: 31326319 Free article. Clinical Trial.
The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases.
Birring SS, Bushnell DM, Baldwin M, Mueller H, Male N, Rohr KB, Inoue Y. Birring SS, et al. Among authors: rohr kb. Eur Respir J. 2022 Jun 2;59(6):2101790. doi: 10.1183/13993003.01790-2021. Print 2022 Jun. Eur Respir J. 2022. PMID: 34764181 Free PMC article.
Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis.
Wijsenbeek M, Swigris JJ, Inoue Y, Kreuter M, Maher TM, Suda T, Baldwin M, Mueller H, Rohr KB, Flaherty KR; INBUILD Trial Investigators. Wijsenbeek M, et al. Among authors: rohr kb. Eur Respir J. 2024 Feb 1;63(2):2300752. doi: 10.1183/13993003.00752-2023. Print 2024 Feb. Eur Respir J. 2024. PMID: 38135442 Free PMC article. Clinical Trial.
31 results